BPC-157 + TB-500 Set

BPC-157 10mg

A synthetic pentadecapeptide studied in in-vitro models of tissue-repair signalling and cellular migration.

Certificate of Analysis: LU-BC10-0626-A

TB-500 5mg

A thymosin beta-4 fragment investigated in research on cellular migration and angiogenesis pathways.

Certificate of Analysis: J_0726-01-TB500

BPC-157

BPC-157 traces back to a question asked at the University of Zagreb in 1975: if the stomach lining survives its own acid, does gastric juice contain something protective? Predrag Sikirić assembled a team in 1981 that collected human gastric juice from hospital gastroenterology clinics and screened the fractions for protective activity. In 1989 the group reported isolating the active fragment, and the synthetic pentadecapeptide was formally described in 1993. It is a 15-amino-acid sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight 1419.55 Da — derived from a larger protein found in gastric juice. Unusually for a peptide, it is stable in human gastric juice, which is why the original work was possible at all.

The published literature characterises BPC-157 in animal and in-vitro models as a cytoprotective agent, with reported activity on angiogenic signalling (VEGFR2 pathway), nitric oxide system interaction, and growth-factor expression in gastrointestinal and connective tissue models. The great majority of this work is preclinical — rodent and cell-culture studies. It has not been approved by the FDA for any human use, and human clinical data remains extremely limited.

1. 1.Current Pharmaceutical Design, 2018. PMID 29879879 — vascular recruitment and cytoprotective signalling in the gastrointestinal tract (title not reproduced here)
2. 2.Int. J. Molecular Sciences, 2026. PMID 41898733 — a review of the tissue-repair literature (title not reproduced here)

TB-500

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a 43-amino-acid peptide originally isolated from bovine thymus tissue. Its complete amino acid sequence was published in the Proceedings of the National Academy of Sciences in 1981, following work through the 1960s and 70s on biologically active thymus extracts — at that point it was understood as a thymic hormone and studied for its effect on thymocyte populations. The reframing came later, when Tβ4 was identified as a major G-actin sequestering protein. That reclassification, from immune factor to regulator of the cytoskeleton, is the reason the compound appears in tissue-repair literature at all.

Thymosin beta-4 is characterised as a principal G-actin sequestering peptide in mammalian cells: it binds monomeric (G-)actin and influences the balance between free monomer and polymerised filament, which governs cytoskeletal remodelling and cell migration. Later work has examined it as a target of hypoxia-inducible nitric oxide and HIF-1α regulation in cell-culture models. All of this is preclinical and in vitro. TB-500 is not FDA-approved for human use, and thymosin beta-4 is on the WADA Prohibited List.

1. 1.“Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations.” PNAS, 1981. PMID 6940133
2. 2.“The actin-sequestering protein thymosin beta-4 is a novel target of hypoxia-inducible nitric oxide and HIF-1α regulation.” PLoS ONE, 2014. PMID 25271630
3. 3.“Thymosin Beta-4, Actin-Sequestering Protein Regulates Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Nitric Oxide.” Biomolecules & Therapeutics, 2015. PMID 25593639
4. 4.WADA Prohibited List — World Anti-Doping Agency